Evidence map›Paper›PMID 42572056›Full record

ReviewCurrent pain and headache reports2026

GLP-1-Based Therapies in Pain Medicine: A Narrative Review and Expert Opinion on Obesity-Related Low Back and Knee Pain.

Jamal Hasoon, Anvinh Nguyen, Omar Viswanath, Ivan Urits, Christopher L Robinson

Abstract readReview
PubMed Publisher
In one paragraph

Review in Current pain and headache reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Jamal HasoonDepartment of Anesthesiology, Critical Care, and Pain Medicine, University of Texas Health Science Center at Houston, Houston, TX, USA. Jamal.J.Hasoon@uth.tmc.edu.
Anvinh NguyenDepartment of Anesthesiology, Baylor College of Medicine, Houston, TX, USA.
Omar ViswanathDepartment of Anesthesiology, Critical Care, and Pain Medicine, University of Texas Health Science Center at Houston, Houston, TX, USA.
Ivan UritsDepartment of Pain Management, Southcoast Health, Wareham, MA, USA.
Christopher L RobinsonDepartment of Anesthesiology and Critical Care, Division of Pain Medicine, The Johns Hopkins University School of Medicine, Baltimore, MD, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purpose of reviewObesity is highly prevalent among patients with chronic musculoskeletal pain and is associated with low back pain, knee osteoarthritis, reduced mobility, and poorer functional outcomes. Glucagon-like peptide-1 (GLP-1) receptor agonists and related therapies have transformed obesity medicine and may become more relevant to pain medicine specialists. This narrative review examines whether GLP-1-based medications should be considered within pain practice, particularly for obesity-associated low back pain and knee osteoarthritis. RECENT

findingsChronic pain impacts a substantial portion of adults, while low back pain and osteoarthritis remain leading causes of disability worldwide. Obesity is associated with low back pain and knee osteoarthritis, and weight reduction has been shown to improve pain and function in these conditions. GLP-1-based therapies can produce clinically meaningful weight loss in patients with obesity and chronic pain. Literature also suggests possible anti-inflammatory and chondroprotective effects relevant to pain. GLP-1-based medications should not be viewed as primary analgesics or replacements for standard pain evaluation, rehabilitation, pharmacologic care, or interventional treatment. However, they are reasonable to consider as part of comprehensive pain management in patients with obesity when excess weight plausibly contributes to chronic pain, impaired mobility, or reduced rehabilitation tolerance. Pain physicians familiar and comfortable with obesity pharmacotherapy may consider prescribing within appropriate indications and safety parameters. Alternatively, referral to obesity medicine, endocrinology, primary care, or another experienced clinician is appropriate.

Indexed as

Chronic PainGlucagon-Like Peptide 1Low Back PainObesityOsteoarthritis, KneePain ManagementGlucagon-Like Peptide-1 Receptor AgonistsHumansGlucagon-Like Peptide 1Glucagon-Like Peptide-1 Receptor AgonistsChronic painGLP-1 receptor agonistsKnee osteoarthritisLiraglutideLow back painObesityPain medicineSemaglutideTirzepatideWeight loss

Identifiers

PMID42572056

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.